Phase 1 N=41 A Study of OsrHSA in Adult Healthy Male and Female Volunteers
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliary Clearance in Healthy Subjects
Healthy Subjects
Primary: Change in Whole Lung Mucociliary Clearance — 0.6; -4.0 % Clearance — p=<.05
N/A N=120 Evaluation of Physiological Variables and Detection of Blood Loss in Healthy Adults With Different Subject Positioning by the CM-1500
Fluid Loss · Blood Loss
Primary: Impact of Subject Positioning on Percent Change of Heart Rate (HR) After Minor Blood Loss (e.g., 500mL) — 10.7; 14.7 percent change
N/A N=18 Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - the Pilot 2 Study - Healthy Subjects
Healthy
Primary: Performance: EEG Recordings - Impedance — 2.3 Impedance (kOhm)
Phase 1 N=48 Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)
Anesthesia; Adverse Effect · Cardiac Arrhythmia
Primary: Change-from-baseline in QTc Interval — 2.1; 5.1; -0.1; 4.1 ms — p=<0.05
N/A N=984 Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks
Smoking
Primary: Levels of High Density Lipoprotein C (HDL-C). — 54.1; 50.9; 56.3; 52.8 mg/dL — p=<0.001
Phase 4 N=74 Continuous Glucose Sensor Profiles in Non-Diabetic Subjects
Healthy Subjects Without Type 1 Diabetes
Primary: Overall Mean Sensor Glucose by Age Group — 98; 103; 97; 96 mg/dL — p=0.009
N/A N=25 Nicotine Pharmacokinetic Study of Heated Tobacco and Heated Herbal Products
Healthy Volunteers
Primary: Nicotine Cmax — 13.00; 12.97; 6.00; 6.87 ng/mL
N/A N=13 Clinical Trial Testing the BioSerenity Pulse Oximeter (EOXY) Efficacy, Performance and Safety in Healthy Volunteer
Healthy
Primary: Percentage SPO2 Accuracy Root-Mean Square (ARMS) at Forehead Position — 3.91; 3.08; 3.36; 2.85 percentage of ARMS (accuracy)
N/A N=160 Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting
Smoking
Primary: Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA) — 106.25; 460.15; 91.73 pg/mg creat — p=<0.001
N/A N=77 Clinical Evaluation of the CM-1500 During Apheresis Blood Donation
Fluid Loss
Primary: Characterize Changes in the Relative Index During an Apheresis Procedure — 94.9; 99.3 Relative Index
N/A N=24 Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics
Moderate to Severe Asthma
Primary: Change in MCC From Baseline to 7% Post Hypertonic Saline Inhalation — 29.9 percent clearance — p=<0.001
N/A N=160 Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.
Smoking
Primary: Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA) — 194.05; 2314.37; 168.01 pg/mg creat — p=<0.001
N/A N=16 Active and Passive Music Therapy Interventions
Autonomic Nervous System Imbalance · Hypothalamic Pituitary Adrenal Axis Suppression
Primary: Change From Baseline to Post Intervention High Frequency (HF) and Low Frequency Divided by High Frequency (LF/HF) Power Amplitude — 0.1796; 0.1507; -0.3872; 0.3731…
Phase 1 N=20 BI 409306 Cardiac Safety Trial in Healthy Volunteers
Healthy
Primary: Slope of the Placebo-corrected Change From Baseline of Heart Rate at Rest and Plasma Concentration Between 0 to 10 Hours — 0.80; 5.46 beats/min
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 2 N=60 RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With Adverse Events — 0; 0; 2; 3 Participants
Phase 1 N=12 Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects
Arthritis, Rheumatoid
Primary: Part 1: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL) 6 for LPS Arm — 2.4086; 0.2798…
Phase 1 N=15 A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors
Advanced Solid Tumor
Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants
N/A N=160 Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
Smoking
Primary: Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA) — 83.21; 617.04; 83.57 pg/mg creat — p=<.001
N/A N=24 A Randomised, Cross-Over, Nicotine Pharmacokinetic and Pharmacodynamic Study of Heated Tobacco Products Compared to Combustible Cigarettes
Healthy Volunteers
Primary: Nicotine Cmax — 10.500; 7.539; 8.191; 21.680 ng/mL
N/A N=60 Pharmacokinetic and Subjective Effects of Heated Tobacco Products
Tobacco Use
Primary: Baseline-adjusted Plasma Nicotine Concentration Pharmacokinetic (PK) Parameters [Cmax] Assessment — 6.426; 7.953; 8.288; 7.993 ng/mL
N/A N=50 Sleep in Pediatric HSCT
Sleep · Stem Cell Transplant Complications
Primary: Patient Acceptability Questionnaire — 3.63; 3.55 units on a scale
N/A N=200 Urinalysis Results in Healthy Individuals
Asymptomatic Bacteriuria · Asymptomatic Pyuria
Primary: False Positive Urine — 6; 40 Participants
N/A N=27 Novel Non-Invasive Monitoring Parameter in Healthy Volunteers
No Conditions · Focus is Respiratory Rate
Primary: The Covidien Nellcor Respiration Rate Software Shall Determine Respiration Rate Measured as Mean and Standard Deviation With Accuracy That is Non-inferior to Predicate…
N/A N=974 Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking
Inflammation · Oxidative Stress · Smoking
Primary: Carboxyhemoglobin (COHb) in Blood — 3.07; 1.52; 1.49 % of CO saturated hemoglobin — p=<0.001
Phase 1 N=109 Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 34783.4; 35889.9; 37370.3 µg·h/mL
Phase 1 N=12 A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
Respiratory Syncytial Viruses
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
N/A N=160 Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting
Smoking
Primary: Concentration of Monohydroxybutenylmercapturic Acid (MHBMA) — 110.96; 882.25; 94.97 pg/mg creat — p=<0.001